The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease

被引:0
作者
Hershenson, Roy [1 ,2 ]
Nardi-Agmon, Inbar [1 ,2 ,3 ]
Leshem-Lev, Dorit [2 ,3 ]
Kornowski, Ran [1 ,2 ]
Eisen, Alon [1 ,2 ]
机构
[1] Rabin Med Ctr, Dept Cardiol, 39 Jabotinsky St, IL-49100 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Felsenstein Med Res Ctr, Petah Tiqwa, Israel
关键词
Diabetes and cardiovascular disease; Endothelial progenitor cells; Cardioprotective effects of anti-diabetic medications; CARDIOVASCULAR OUTCOMES; MIGRATORY ACTIVITY; SGLT-2; INHIBITORS; PERIPHERAL-BLOOD; HEART-FAILURE; RISK-FACTORS; NUMBER; MECHANISMS; GLICLAZIDE; PROFILE;
D O I
10.1186/s12933-024-02466-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundDiabetes mellitus (DM) is associated with premature atherosclerotic disease, coronary artery disease (CAD) and chronic heart failure (HF), leading to increased morbidity and mortality. Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) exhibit cardioprotective benefits beyond glucose lowering, reducing the risk of major cardiovascular events (MACE) and HF hospitalizations in patients with DM and CAD. Endothelial progenitor cells (EPCs) are bone marrow-derived cells involved in vascular repair, mobilized in response to vascular injury. The number and function of circulating EPCs (cEPCs) are negatively affected by cardiovascular risk factors, including DM. This study aimed to examine the response of cEPCs to SGLT2i treatment in DM patients with stable CAD.MethodsA prospective single-center study included patients with DM and stable CAD who were started on an SGLT2i (empagliflozin). Peripheral blood samples were collected at baseline, 1 month, and 3 months to evaluate cEPC levels and function by flow cytometry, immunohistochemistry and MTT assays.ResultsEighteen patients were included in the study (median age 73, (IQR 69, 77) years, 67% male). After 1 month of treatment with empagliflozin, there was no significant change in cEPCs level or function. However, following 3 months of treatment, a significant increase was observed both in cell levels (CD34(+)/VEGFR-2(+): from 0.49% (IQR 0.32, 0.64) to 1.58% (IQR 0.93, 1.82), p = 0.0006; CD133(+)/VEGFR-2(+): from 0.38% (IQR 0.27, 0.6) to 0.82% (IQR 0.7, 1.95), p = 0.0001) and in cell function (from 0.25 CFUs (IQR 0, 0.5) at baseline, to 2 CFUs (IQR 1, 2) at 3 months, p = 0.0012).ConclusionsEmpagliflozin treatment in patients with DM and stable CAD increases cEPC levels and function, implying a cardioprotective mechanism. These findings highlight the potential of SGLT2i in treating cardiovascular diseases, warranting further research to explore these effects and their long-term implications.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease
    Padfield, Gareth J.
    Tura-Ceide, Olga
    Freyer, Elizabeth
    Barclay, George Robin
    Turner, Marc
    Newby, David E.
    Mills, Nicholas L.
    HEART, 2013, 99 (11) : 791 - 798
  • [32] The Role of Endothelial Progenitor Cells in Coronary Artery Disease: Basic Molecular Mechanisms and Its Clinical Potentials
    Oktaviono, Yudi Her
    Hutomo, Suryo Ardi
    Luke, Kevin
    INDONESIAN BIOMEDICAL JOURNAL, 2021, 13 (02): : 106 - 113
  • [33] Predictors of circulating endothelial progenitor cell levels in patients without known coronary artery disease referred for multidetector computed tomography coronary angiography
    Bettencourt, Nuno
    Oliveira, Susana
    Toschke, Andre Michael
    Rocha, Joao
    Leite, Daniel
    Carvalho, Monica
    Xara, Sonia
    Schuster, Andreas
    Chiribiri, Amedeo
    Leite-Moreira, Adelino
    Nagel, Eike
    Alves, Helena
    Gama, Vasco
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2011, 30 (10) : 753 - 760
  • [34] Effect of Aliskiren on Circulating Endothelial Progenitor Cells and Vascular Function in Patients With Type 2 Diabetes and Essential Hypertension
    Raptis, Athanasios E.
    Markakis, Konstantinos P.
    Mazioti, Maria C.
    Ikonomidis, Ignantios
    Maratou, Eirini P.
    Vlahakos, Dimitrios V.
    Kotsifaki, Eleni E.
    Voumvourakis, Asterios N.
    Tsirogianni, Alexandra G.
    Lambadiari, Vaia A.
    Lekakis, John P.
    Raptis, Sotirios A.
    Dimitriadis, George D.
    AMERICAN JOURNAL OF HYPERTENSION, 2015, 28 (01) : 22 - 29
  • [35] Circulating Progenitor Cells Predict Clinical Outcomes in Patients With Coronary Artery Disease and Renal Insufficiency
    Vlachogiannis, Nikolaos I.
    Stellos, Konstantinos
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2020, 5 (08): : 783 - 785
  • [36] Circulating endothelial progenitor cells and endothelial cells in moyamoya disease
    Bao, Xiang-Yang
    Fan, Yan-Na
    Liu, Yi
    Wang, Qian-Nan
    Zhang, Yong
    Zhu, Bing
    Liu, Bing
    Duan, Lian
    BRAIN AND BEHAVIOR, 2018, 8 (09):
  • [37] Endothelial progenitor cells are associated with plasma homocysteine in coronary artery disease
    Huang, Chaoyang
    Zhang, Li
    Wang, Zhankun
    Pan, Huiyun
    Zhu, Jianhua
    ACTA CARDIOLOGICA, 2011, 66 (06) : 773 - 777
  • [38] Hypermethylation of DDAH2 promoter contributes to the dysfunction of endothelial progenitor cells in coronary artery disease patients
    Niu, Pan-Pan
    Cao, Yu
    Gong, Ting
    Guo, Jin-Hui
    Zhang, Bi-Kui
    Jia, Su-Jie
    JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [39] Coronary Artery Disease in Aging Women: A Menopause of Endothelial Progenitor Cells?
    Hutter, Randolph
    Badimon, Juan Jose
    Fuster, Valentin
    Narula, Jagat
    MEDICAL CLINICS OF NORTH AMERICA, 2012, 96 (01) : 93 - +
  • [40] Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease
    Mason, Tamique
    Coelho-Filho, Otavio R.
    Verma, Subodh
    Chowdhury, Biswajit
    Zuo, Fei
    Quan, Adrian
    Thorpe, Kevin E.
    Bonneau, Christopher
    Teoh, Hwee
    Gilbert, Richard E.
    Leiter, Lawrence A.
    Juni, Peter
    Zinman, Bernard
    Jerosch-Herold, Michael
    Mazer, C. David
    Yan, Andrew T.
    Connelly, Kim A.
    JACC-CARDIOVASCULAR IMAGING, 2021, 14 (06) : 1164 - 1173